Molecular Templates Inc Share Price Today (NASDAQ: MTEM)

Name: Molecular Templates Inc Share Price (NASDAQ: MTEM) - Stock Quote, Live Chart
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Molecular Templates Inc share price is $0 & ₹0.00 as on 5 Jan 2025 IST

▲

-0.03

(-100%)

Market is closed - opens 7 PM, 30 Jun 2025

The stock has been delisted from the stock exchange on 6 Jan 2025

View live Molecular Templates Inc share price in Dollar and Rupees. Guide to invest in Molecular Templates Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Molecular Templates Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Molecular Templates Inc (MTEM) Key Statistics

in dollars & INR

Previous Close	$0.03
Open	$0.03
Market Capitalization	$199.5K
Today's Volume	$123.6K
Revenue TTM	$25.5M
EBITDA	$-13.9M
Earnings Per Share (EPS)	$-3.05
Profit Margin	-61.35%
Quarterly Earnings Growth YOY	-0.97%
Return On Equity TTM	-929.14%

How to invest in Molecular Templates Inc Stock (MTEM) from India?

It is very easy for Indian residents to invest directly in Molecular Templates Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Molecular Templates Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Molecular Templates Inc or MTEM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Molecular Templates Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Molecular Templates Inc shares which would translate to null fractional shares of Molecular Templates Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Molecular Templates Inc, in just a few clicks!

Global Institutional Holdings in Molecular Templates Inc

Bellevue Group AG
19.44%
SILVERARC CAPITAL MANAGEMENT, LLC
9.48%
Bvf Inc
7.93%
Bank of Montreal
1.11%
BMO Capital Markets Corp.
1.11%
Vanguard Group Inc
0.77%

Analyst Recommendation on Molecular Templates Inc

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Molecular Templates Inc(by analysts ranked 0 to 5 stars)

MTEM Molecular Templates Inc Financials in INR & Dollars

Revenue

Profit

Cash Flow

Annually

Quarterly

FY18

FY19

FY20

FY21

FY22

FY23

	FY23	Y/Y Change
Revenue	$57.3M	↑ 190.1%
Net Income	$-8.1M	↓ 91.24%
Net Profit Margin	-14.18%	↑ 455.18%

Q1 FY23

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

	Q2 FY24	Q/Q Change
Revenue	$572.0K	↓ 94.84%
Net Income	$-8.1M	↓ 1515.56%
Net Profit Margin	-1.4K%	↓ 1420.72%

FY18

FY19

FY20

FY21

FY22

FY23

	FY23	Y/Y Change
Profit	$50.4M	↑ 321.57%

Q1 FY23

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

	Q2 FY24	Q/Q Change
Profit	$-4.8M	↓ 148.62%

FY18

FY19

FY20

FY21

FY22

	FY22	Y/Y Change
Operating Cash Flow	$-89.0M	↑ 192.97%
Investing Cash Flow	$95.3M	↓ 252.65%
Financing Cash Flow	$-265.0K	↓ 100.29%

Q1 FY23

Q2 FY23

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-9.6M	↓ 50.22%
Investing Cash Flow	$3.1M	↓ 87.92%
Financing Cash Flow	$-27.5M	↑ 0.0%

About Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Organization	Molecular Templates Inc
Employees	62
CEO	Dr. Eric E. Poma Ph.D.
Industry	Health Technology

Management People of Molecular Templates Inc

Name	Title
Dr. Eric E. Poma Ph.D.	Interim CFO, Treasurer, Principal Acc. Officer, CEO, Chief Scientific Officer & Director
Ms. Kristen Quigley B.A.	Chief Operating Officer
Dr. Grace Kim	Chief Strategy Officer & Head of IR
Dr. Michelle Iwamoto-Fan J.D., Ph.D.	Senior Vice President & General Counsel
Dr. Joseph Phillips Ph.D.	Senior VP & Head of CMC Development
Dr. Chris Moore Ph.D.	Senior VP and Head of Preclinical Development & Translational Medicine

Important FAQs about investing in MTEM Stock from India :

Can Indians buy Molecular Templates Inc shares?

Yes, Indians can invest in the Molecular Templates Inc (MTEM) from India.

With INDmoney, you can buy Molecular Templates Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Molecular Templates Inc at zero transaction cost.

How can I buy Molecular Templates Inc shares from India?

It is very easy to buy Molecular Templates Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Molecular Templates Inc (MTEM) be purchased?

Yes, you can buy fractional shares of Molecular Templates Inc with INDmoney app.

What are the documents required to start investing in Molecular Templates Inc stocks?

To start investing in Molecular Templates Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Molecular Templates Inc?

Today's market capitalisation of Molecular Templates Inc MTEM is 199.5K

Who is the Chief Executive Officer (CEO) of Molecular Templates Inc ?

Dr. Eric E. Poma Ph.D. is the current Chief Executive Officer (CEO) of Molecular Templates Inc.

Discover More

Allete Inc
$63.92
-0.12%
South Plains Financial Inc
$35.73
-0.33%
Pimco Municipal Income Fund
$7.87
-0.13%
Rtx Corp
$144.64
+1.38%
Abrdn Global Dynamic Dividend Fund
$10.89
+0.93%
Columbia Semiconductor & Technology Etf
$27.55
+0.62%
Blackrock Ltd Duration Inc
$14.17
+0.78%
Cp High Yield Trend Etf
$21.68
-0.05%
John Hancock Investors Closed Fund
$13.76
+0.73%

Explore all

	FY18	Y/Y Change
Revenue	$7.3M	↑ 202.45%
Net Income	$-30.3M	↑ 30.89%
Net Profit Margin	-415.86%	↑ 545.1%

	FY19	Y/Y Change
Revenue	$19.5M	↑ 167.73%
Net Income	$-69.5M	↑ 129.59%
Net Profit Margin	-356.62%	↑ 59.24%

	FY20	Y/Y Change
Revenue	$18.8M	↓ 3.35%
Net Income	$104.9M	↓ 250.88%
Net Profit Margin	556.73%	↑ 913.35%

	FY21	Y/Y Change
Revenue	$38.7M	↑ 105.34%
Net Income	$-79.3M	↓ 175.6%
Net Profit Margin	-204.96%	↓ 761.69%

	FY22	Y/Y Change
Revenue	$19.8M	↓ 48.95%
Net Income	$-92.7M	↑ 16.9%
Net Profit Margin	-469.36%	↓ 264.4%

	Q1 FY23	Q/Q Change
Revenue	$33.6M	↑ 1187.9%
Net Income	$8.5M	↓ 138.6%
Net Profit Margin	25.31%	↑ 869.78%

	Q2 FY23	Q/Q Change
Revenue	$6.6M	↓ 80.29%
Net Income	$-10.9M	↓ 227.71%
Net Profit Margin	-164.0%	↓ 189.31%

	Q3 FY23	Q/Q Change
Revenue	$6.8M	↑ 2.55%
Net Income	$4.2M	↓ 138.21%
Net Profit Margin	61.11%	↑ 225.11%

	Q4 FY23	Q/Q Change
Revenue	$7.0M	↑ 3.24%
Net Income	$-3.9M	↓ 195.06%
Net Profit Margin	-56.27%	↓ 117.38%

	Q1 FY24	Q/Q Change
Revenue	$11.1M	↑ 58.01%
Net Income	$572.0K	↓ 114.49%
Net Profit Margin	5.16%	↑ 61.43%

	FY18	Y/Y Change
Operating Cash Flow	$-4.5M	↓ 68.7%
Investing Cash Flow	$-15.9M	↓ 264.13%
Financing Cash Flow	$49.2M	↓ 20.28%

	FY19	Y/Y Change
Operating Cash Flow	$-25.2M	↑ 465.38%
Investing Cash Flow	$-39.7M	↑ 149.13%
Financing Cash Flow	$65.7M	↑ 33.48%

	FY20	Y/Y Change
Operating Cash Flow	$-83.8M	↑ 231.95%
Investing Cash Flow	$-34.7M	↓ 12.74%
Financing Cash Flow	$58.9M	↓ 10.35%

	FY21	Y/Y Change
Operating Cash Flow	$-30.4M	↓ 63.74%
Investing Cash Flow	$-62.4M	↑ 80.13%
Financing Cash Flow	$92.6M	↑ 57.22%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-19.4M	↑ 5.04%
Investing Cash Flow	$26.0M	↓ 8.44%
Financing Cash Flow	$-27.5M	↑ 9936.5%